Targeted protein degradation (TPD) is an innovative field that is revolutionising drug development, with various modalities being explored by researchers to tackle undruggable targets and treat a wide range of diseases, including cancer, neurological disorders, and skin diseases.In this episode, Sofia Rodriguez talks to Alessio Ciulli, professor of chemical structural biology at the University of Dundee and co-founder of Amphista Therapeutics, the leading Europe-based TPD company. Join us to hear about his lab's ground-breaking research into protein degradation, the opening of the new Centre for Targeted Protein Degradation (CeTPD), and the opportunities and challenges of novel degrader design.